Physician profile
Taz Thomas
NPI 1629080569
$11,027.51
in general payments reported to CMS, 2019-2025
31 companies · $2,010 in 2025
The $2,010 reported for 2025 was more than what 93% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,736 · 2022: $2,468 · 2023: $2,820 · 2024: $1,994 · 2025: $2,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,824.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,824.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,791.47 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,233.38 | 2021-2025 | Caplyta |
| Corium, LLC | $871.89 | 2021-2025 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $848.43 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Lundbeck LLC | $752.71 | 2021-2025 | Rexulti, Brintellix, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $609.91 | 2022-2025 | Sunosi, Auvelity |
| Alkermes, INC. | $604.84 | 2022-2025 | Lybalvi, Aristada |
| Neos Therapeutics, Lp | $553.40 | 2021-2023 | Adzenys Xr-Odt |
| Neurocrine Biosciences, INC. | $470.12 | 2024-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $456.06 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Tris Pharma INC | $394.19 | 2023-2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $392.16 | 2021-2023 | Trintellix |
| Sunovion Pharmaceuticals INC. | $351.58 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $324.29 | 2021-2025 | Fanapt, Hetlioz |
| Bausch Health US, LLC | $260.75 | 2021-2025 | Aplenzin |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $181.57 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $173.01 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Jazz Pharmaceuticals INC. | $115.25 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $109.72 | 2022-2024 | Jornay Pm |
| Merck Sharp & Dohme LLC | $89.75 | 2021-2023 | Belsomra |
| Vertical Pharmaceuticals, LLC | $75.62 | 2025 | Relexxii |
| E.R. Squibb & Sons, L.L.C. | $75.46 | 2025 | Cobenfy |
| Almatica Pharma LLC | $70.40 | 2021-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $48.93 | 2024 | Secuado, Xelstrym |
| Alfasigma USA, INC. | $33.69 | 2022 | |
| Supernus Pharmaceuticals, INC. | $31.36 | 2023 | Qelbree |
| Aytu Biopharma, INC. | $28.67 | 2021 | |
| Idorsia Pharmaceuticals US INC | $27.74 | 2024 | Quviviq |
| Biogen, INC. | $20.00 | 2024 | |
| Eisai INC. | $18.27 | 2021 | |
| Livanova USA, INC. | $12.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taz Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.